Marker Therapeutics Inc
markertherapeutics.comMarker Therapeutics (NASDAQ: MRKR) is a clinical-stage biopharmaceutical company developing non-genetically engineered T cell therapies for cancer. The company generates no product revenue as of FY2025, funding operations through grant income from government agencies and non-profit foundations under cost-reimbursement arrangements, along with equity offerings via an at-the-market (ATM) agreement. Its lead product, MT-601, is a multiTAA-specific T cell therapy being developed for lymphoma, with a pivotal trial (APOLLO study) anticipated to commence in 2026. Manufacturing of MT-601 is conducted through third-party CDMOs, including Baylor College of Medicine (BCM) for ongoing clinical supply and Cellipont Bioservices under a Statement of Work entered June 16, 2025 for scale-up and cGMP production. The company has incurred recurring losses, pays no dividends, and lists common stock on the Nasdaq Capital Market under the symbol MRKR. As of March 16, 2026, the stock traded at $1.41 per share with 39 stockholders of record.
Products & Services
MT-601: a non-genetically engineered, multiTAA-specific T cell (MAR-T cell) therapy in clinical development for lymphoma. No products are approved or commercialized as of the FY2025 10-K filing.
Revenue Model
Grant income recognized on a cost-reimbursement basis from government agencies and non-profit foundations as qualifying research and development expenses are incurred. No product revenue was generated during the two years ended December 31, 2025. Additional funding comes from equity issuances under an ATM agreement.
Customers & Markets
No commercial customers as of FY2025. End market is oncology, specifically lymphoma patients. Funding counterparties are government agencies and non-profit foundations providing research grants.
Financial Snapshot
Loading...
